ClinicalTrials.gg
CompletedNCT07275866Updated Oct 23, 2026

Multi-strain Probiotic Effects on Self-Reported Constipation

An interventional study of Multi-strain probiotics in Constipation, Probiotic and Probiotic Intervention, sponsored by Dr Anthony Hobson. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Dr Anthony Hobson · Not applicable, Interventional, and Treatment

Updated Oct 23, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 61 studies in Constipation with a site in United Kingdom — 4 open to participants now, 5 under way, none of them phase 3. Constipation · United Kingdom.

Enrollment
42nd of 54
20 · median 93
Started
2025
with 2 others
No phase
23 of 61
2 open now
Registered
58th of 61
by date

Among the 61 studies in Constipation with a site in United Kingdom, this one is the 42nd largest by enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2025, is one of 23 with no phase, and was the 58th registered.

Constipation

1,048 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

4 of the 61 studies in Constipation with a site in United Kingdom are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Constipation with a site in United Kingdom, or all of them as a file.
02

Study summary

Constipation is a prevalent gastrointestinal condition. Beyond simple lifestyle measures (e.g. increasing fibre intake, hydration, levels of exercise), medical therapies are available for management. However, a sizeable number of sufferers are dissatisfied with drug treatments (either over-the-counter or prescribed), meaning there is an unmet need for alternative therapeutic strategies.

Pre, pro- and synbiotics have emerged as one alternative treatment, and a growing body of evidence now supports their use in a proportion of individuals with mild constipation. However, it is currently not possible to predict which individuals may benefit. A better understanding of an individuals' symptoms and underlying pathophysiology may allow for more targeted treatment.

The multistrain live bacterial food product (probiotic) being tested contains billions of live and active bacteria that has been shown to improve symptoms in the irritable bowel syndrome (IBS: which is 'constipation-predominant' in many). Notably, improvements ('completely resolved' or 'some positive difference') in bowel habit satisfaction, abdominal pain, bloating and urgency, as well as on quality of life have been shown after 4 or more weeks of this probiotc.

This study aims to have 20 participants with self-reported constipation to assess improvements in constipation symptoms, quality of life and measures of gut function.

03

Conditions studied

  • Constipation
  • Probiotic
  • Probiotic Intervention

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant has provided written before participating in the study after being given a full description of the study and prior to any study-specific procedures being performed.
  2. Participant has Cleveland Clinic constipation score (CCCS) of 9-16 at screening call
  3. Participant is willing to discontinue all other therapies for constipation and undergo washout where applicable.
  4. Participant is a male or non-pregnant female and is 18-70 years of age
  5. If participant is willing to adhere to one of the following methods of :

    i) Hormonal contraception e.g. the 'pill' or an implant ii) Intrauterine device (IUD) iii) Intrauterine hormone-releasing system (IUS) vi) Sexual abstinence (if it is in line with participants' preferred and usual lifestyle).

    or has had a: v) Hysterectomy or has a: vi) Vasectomised partner

  6. Participant can communicate well with the Investigator and to comply with the requirements for the entire study.
  7. Participant has capacity to understand written English.
  8. Participant has a (BMI) of 18.5 - 39.9kg/m2 (bounds included).
  9. Participant agrees to follow all pre-test preparation for the ATMO capsule transit study.

Exclusion criteria

Exclusion Criteria:

  1. Women who are pregnant and/or breastfeeding.
  2. Participants who are planning to significantly change their diet (e.g. weight loss program, becoming vegetarian) during the study period.
  3. Participant has had diarrhoea within 7 weeks of screening period.
  4. Prior abdominal surgery involving resection of the small or large bowel.
  5. Prior bariatric surgery involving resection of the stomach or by-pass procedures.
  6. Type 1 diabetes mellitus.
  7. Known organic or structural GI disease including:

    • Coeliac disease
    • Inflammatory bowel disease
    • Diverticulitis
    • Small bowel strictures
  8. Irritable bowel syndrome where the predominant symptom is pain (assessed via screening questions).
  9. Oropharyngeal dysphagia or difficulty swallowing capsules.
  10. Any other medical condition that the investigator deems may confound results or affect participants' safety in the study.
  11. Any use of prohibited medication that the participant cannot complete appropriate for.
  12. Insufficient knowledge of English to complete the daily bowel diary.
  13. Allergy to any component of the supplement, motility bar, lactulose or Zoe blue cookie.
  14. Participant is involved in this study as an investigator, sub-Investigator, study coordinator, other study staff, or Sponsor member.
  15. Previous use of the probiotic Symprove.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Multi-strain Liquid Probiotic

    70ml of a multi-strain liquid probiotic taken daily for 28-35 days

    Dietary Supplement: Multi-strain probiotics

Interventions

  • Dietary supplementMulti-strain probiotics

    28-35 days of 70 ml Symprove once daily, to be taken on an empty stomach upon waking. 10 minutes should be taken between ingestion of Symprove before eating and drinking.

06

What researchers measure

Primary outcomes

  1. Patient Assessment of Constipation-Symptoms (PAC-SYM)

    Number of participants with clinically meaningful change in PAC-SYM score (reduction of \>0.6 or \>0.75 points). The PAC-SYM questionnaire is a 12 item validated patient-reported measure of severity of constipation symptoms during the past two weeks.

    Time frame: Pre-post comparison (28 days)

Secondary outcomes

  1. Patient Assessment of Constipation - Quality of Life (PAC-QoL)

    Number of participants with clinically meaningful change in PAC-QoL (reduction of \>0.5 or \>1.0 point). A validated questionnaire consisting of 28 items to measure the impact of constipation on a patient's quality of life.

    Time frame: Pre-Post comparison (28 days)

  2. Participant Compliance

    Number of participants completing \>75% of breath gas measurements and bowel diary submissions with OMED device. The OMED Health Breath Analyzer is used for breath gas readings at 4 intervals during the day. The bowel diary recorded daily on paper throughout the study capturing movements, symptoms and any medication

    Time frame: Pre-Post comparison (28 days)

  3. Whole Gut Transit Time (ATMO)

    Change in whole gut transit time measured by ATMO capsule ATMO capsule is an ingestible electronic medical device measuring gastrointestinal (GI) transit time and environmental conditions as it moves through the digestive tract.

    Time frame: Pre-Post comparison (28 days)

  4. Whole Gut Transit Time (Blue-dye)

    Change in whole gut transit time measured by Blue dye transit study baseline period to treatment period. Participants are required to consume a Zoe blue cookie the following morning after both visits 2 and 3. Participants then report when the blue food colour is visible in their stool, checking every time they pass a bowel movement.

    Time frame: Pre-Post comparison (28 days)

  5. Small Bowel Transit Time (ATMO)

    Change in small bowel transit time measured by ATMO capsule ATMO capsule is an ingestible electronic medical device measuring gastrointestinal (GI) transit time and environmental conditions as it moves through the digestive tract.

    Time frame: Pre-Post comparison (28 days)

  6. Large Bowel Transit Time (ATMO)

    Change in large bowel transit time measured by ATMO capsule ATMO capsule is an ingestible electronic medical device measuring gastrointestinal (GI) transit time and environmental conditions as it moves through the digestive tract.

    Time frame: Pre-Post comparison (28 days)

  7. Gastrointestinal Symptom Rating Scale (GSRS)

    Mean change in GSRS score A validated questionnaire consisting of 15items to assess range of GI symptoms. Scored using a seven-graded Likert scale, where 1 represents the most positive option and 7 the most negative one.

    Time frame: Pre-Post comparison (28 days)

  8. Stool form comparison

    Average stool type recorded in two week baseline compared to average stool type recorded final two weeks of treatment period. Measured using the bristol stool chart reported in bowel habit diary.

    Time frame: Pre-Post comparison (days 1-14 compared to days 29-42)

  9. Stool frequency comparison

    Average stool frequency recorded in two week baseline compared to average stool type recorded final two weeks of treatment period reported in bowel habit diary.

    Time frame: Pre-Post comparison (days 1-14 compared to days 29-42)

  10. Hydrogen and methane production

    Assessment of longitudinal hydrogen and methane production during baseline and treatment periods. Recorded by OMED device 4x daily

    Time frame: Pre-Post comparison (days 1-14 compared to days 15-42)

  11. Global PAC-SYM

    Comparison of global PAC-SYM score from baseline period to treatment period.

    Time frame: Pre-Post comparison (28 days)

  12. Inidividual PAC-SYM

    Comparison of individual PAC-SYM symptom scores from baseline period to treatment period.

    Time frame: Pre-Post comparison (28 days)

  13. Straining

    Self reported straining recorded in two week baseline compared to self reported straining during treatment period reported in bowel habit diary.

    Time frame: Pre-Post comparison (days 1-14 compared to days 15-42)

  14. Sense of complete evacuation

    Self reported sense of complete evacuation recorded in two week baseline compared to self reported Sense of complete evacuation during treatment period reported in bowel habit diary.

    Time frame: Pre-Post comparison (days 1-14 compared to days 15-42)

  15. Time taken for evacuation

    Self reported time taken for evacuation recorded in two week baseline compared to self reported time taken for evacuation during treatment period reported in bowel habit diary.

    Time frame: Pre-Post comparison (days 1-14 compared to days 15-42)

  16. Rescue Medication

    Self reported use of rescue medication recorded in two week baseline compared to self reported use of rescue medication during treatment period reported in bowel habit diary.

    Time frame: Pre-Post comparison (days 1-14 compared to days 15-42)

07

Study locations

1 site
  • The Functional Gut Clinic
    London, NW1 6PU, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2025 to primary completion in Jul 2026, 9 months.

Of 245 non-industry interventional studies with no phase under Constipation, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's 9 months is below that.

Counting every sponsor, half of 316 studies reached it within 14 months; a quarter within 6 and three quarters within 30.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Apr 2026 → Jul 2026 and completion Apr 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2025
First posted
Dec 10, 2025
StartActual
Oct 3, 2025
Primary completionActual
Jul 20, 2026was Apr 2026
CompletionActual
Aug 1, 2026was Apr 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 23, 2026
Primary completion
Apr 2026→Jul 20, 2026 (actual)
Oct 23, 2026
Study completion
Apr 2026→Aug 1, 2026 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Recruiting→Completed
    Primary completion Apr 2026→Jul 20, 2026 (now actual)
    Study completion Apr 2026→Aug 1, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07275866
Lead sponsor
Dr Anthony Hobson
Responsible party
Dr Anthony Hobson (Clinical Director and Senior Clinical GI Scientist, The Functional Gut Clinic) — Sponsor-investigator
First posted
Dec 10, 2025
Start date
Oct 3, 2025
Primary completion
Jul 20, 2026
Completion
Aug 1, 2026
Last update
Oct 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion